FLAMAZINE Cream 1% w/w (Silver sulfadiazine 1% w/w)
Abbreviated Prescribing Information
Please refer to Summary of Product Characteristics (SmPC) before prescribing

**Presentations:** Tube containing 20g or 50g and jars containing 250g or 500g silver sulfadiazine 1% w/w.

**Indications:** Prophylaxis and treatment of infection in burn wounds, leg ulcers and pressure sores. As an aid to the prophylaxis of infection in skin graft donor sites and extensive abrasions. Conservative management of finger-tip injuries where pulp, nail loss and/or partial loss of the distal phalanx has occurred.

**Dosage and Administration:** To be applied topically. **Burns and Leg Ulcers /Pressure Sores:** Apply a layer approx. 3-5mm thick to the affected area using a sterile glove or spatula. Then cover area with an absorbent gauze dressing and support bandage where necessary. Dressing should be changed and FLAMAZINE cream applied at least every 24 hours in burn treatment, or at least three times weekly otherwise, and debridement carried out as necessary. **Finger-Tip Injuries:** Achieve haemostasis of injury prior to application of a 3-5mm layer of FLAMAZINE cream. A conventional finger dressing may be used. Change dressings every 2-3 days.

**Contraindications:** Should not be used at or near term pregnancy, on premature infants or on newborn infants during the first months of life, in patients known to be hypersensitive to sulfonamides, silver sulfadiazine or other components of the cream.

**Precautions & Warnings:** Use with caution in nursing mothers and in the presence of significant hepatic or renal impairment and in individuals known to have G6P deficiency. Not recommended for use in leg or pressure ulcers that are very exudative. Use of FLAMAZINE cream may delay separation of burn eschar and may alter the appearance of burn wounds.

**Interactions:** Silver may inactivate enzymatic debriding agents. With use in large-area burns, effects of oral hypoglycaemic agents and phenytoin may be potentiated.

**Undesirable Effects:** Application site rash, pruritus, burning, leucopenia, renal failure, argyria. Consult SmPC for further information about adverse events.

**Legal Category:** POM
**Product Authorisation No.:** PL 13374/0006
**Cost:** 20g tube: £2.15, 50g tube: £2.81, 250g jar: £8.54, 500g jar: £15.55.
**Marketing Authorisation Holder:** Smith & Nephew Pharmaceuticals Ltd., 101 Hessle Road, Hull, HU3 2BN, England
Further information is available on request from the Marketing Authorisation Holder
**Date of Preparation:** August 2012
**Asset No:**

**Adverse Events should be reported.**

Reporting forms and information can be found at [http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143653](http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143653)

Adverse events should also be reported to Advice@smith-nephew.com